Combination antimicrobial therapy for bacterial infections - Guidelines for the clinician

被引:96
作者
Rybak, MJ
McGrath, BJ
机构
[1] DETROIT RECEIVING HOSP & UNIV HLTH CTR,DEPT PHARM,DETROIT,MI
[2] ANTIINFECT RES LAB,DETROIT,MI
[3] GRACE HOSP,DEPT PHARM,DETROIT,MI
[4] WAYNE STATE UNIV,DETROIT,MI
关键词
D O I
10.2165/00003495-199652030-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Therapy with antimicrobial combinations has been used as long as antimicrobials have been available. Combinations of antibiotics are often used to take advantage of different mechanisms of action and/or toxicity profiles. Well established indications for combination antimicrobial therapy include: (a) empirical treatment of life-threatening infections; (b) treatment of polymicrobial infections; (c) prevention of the emergence of bacterial resistance; and (d) for synergism. Disadvantages of combination therapy include: (a) increased expense; (b) increased risk of adverse effects; (c) antagonism; and (d) superinfection. Combination antimicrobial therapy should be considered for the treatment of serious Gram-negative infections caused by Enterobacter cloacae, Pseudomonas aeruginosa and Serratia marcescens, and certain Gram-positive infections caused by Enterococcus spp. and Staphylococcus spp. Selection of agents should be dependent upon local susceptibility patterns, clinical experience, site of infection, potential toxicities and cost.
引用
收藏
页码:390 / 405
页数:16
相关论文
共 109 条
[51]  
HITCHINGS GH, 1973, TRIMETHOPRIM SULPHAM, P7
[52]   SYNERGISTIC POSTANTIBIOTIC EFFECT OF AMIKACIN AND BETA-LACTAM ANTIBIOTICS ON ENTEROCOCCUS-FAECALIS [J].
ISAKSSON, B ;
HANBERGER, H ;
MALLER, R ;
NILSSON, LE ;
NILSSON, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :9-14
[53]   BETA-LACTAM-RESISTANT ENTEROBACTER BACTEREMIA IN FEBRILE NEUTROPENIC PATIENTS RECEIVING MONOTHERAPY [J].
JOHNSON, MP ;
RAMPHAL, R .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (04) :981-983
[54]   CIPROFLOXACIN AND RIFAMPIN, ALONE AND IN COMBINATION, FOR THERAPY OF EXPERIMENTAL STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
KAATZ, GW ;
SEO, SM ;
BARRIERE, SL ;
ALBRECHT, LM ;
RYBAK, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1184-1187
[55]   PHARMACODYNAMICS OF RP-59500 ALONE AND IN COMBINATION WITH VANCOMYCIN AGAINST STAPHYLOCOCCUS-AUREUS IN AN IN VITRO-INFECTED FIBRIN CLOT MODEL [J].
KANG, SL ;
RYBAK, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1505-1511
[56]   PHARMACODYNAMICS OF LEVOFLOXACIN, OFLOXACIN, AND CIPROFLOXACIN, ALONE AND IN COMBINATION WITH RIFAMPIN, AGAINST METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS IN AN IN-VITRO INFECTION MODEL [J].
KANG, SL ;
RYBAK, MJ ;
MCGRATH, BJ ;
KAATZ, GW ;
SEO, SM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) :2702-2709
[57]   SINGLE, LARGE, DAILY DOSING VERSUS INTERMITTENT DOSING OF TOBRAMYCIN FOR TREATING EXPERIMENTAL PSEUDOMONAS PNEUMONIA [J].
KAPUSNIK, JE ;
HACKBARTH, CJ ;
CHAMBERS, HF ;
CARPENTER, T ;
SANDE, MA .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (01) :7-12
[58]  
KIELHOFNER M, 1992, CLIN INFECT DIS, V14, P403, DOI 10.1093/clinids/14.2.403
[59]  
KORENIOWSKI O, 1982, ANN INTERN MED, V97, P496
[60]  
KOVORIK JA, 1991, ANTIMICROB AGENTS CH, V35, P2167